Trial Profile
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2008 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov.
- 22 Jan 2008 Status change